Clinical trials: Systemic Lupus
Vasculitis, Systemic Lupus Erythematosus (SLE)
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants
The primary objective of this study will be to evaluate the safety and tolerability of single and multiple oral doses of CCX168, over a range of dose levels, in healthy male and female participants.
- Trial name
- NCT05984251
- Testing
- CCX168
- Where
- Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Amgen
Lupus Nephritis
A Study of Guselkumab in Participants With Active Lupus Nephritis
The purpose of this study is to evaluate the efficacy of guselkumab in participants with active lupus nephritis (LN).
- Trial name
- ORCHID-LN (NCT04376827)
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Standard-of-care treatment
- Where
- 60 sites in United States, Argentina and 7 more
- Volunteers
- 33 people
- Sponsor
- Janssen Research & Development, LLC
Lupus Erythematosus, Systemic
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).
- Trial name
- NCT07629583
- Testing
- Cevostamab, Tocilizumab
- Where
- 2 sites in France, Spain
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.
Systemic Lupus Erythematosus
An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus
The aim of this study is to to determine whether atorvastatin 40mg per day is effective in the treatment of SLE.
- Trial name
- NCT00432354
- Testing
- atorvastatin
- Where
- 2 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Lupus Nephritis
A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis
This is a randomized, double-blind, placebo-controlled multicenter clinical study to evaluate the efficacy, safety, and pharmacokinetics of SIM0278 in adult (18-75 years) subjects with active LN suitable for systemic therapy.
- Trial name
- NCT07393451
- Testing
- SIM0278 injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Simcere Pharmaceutical Co., Ltd
Systemic Lupus Erythematosus
A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus
The goal of this open label, dose escalation phase 1b clinical trial is to investigate the safety, tolerability, pharmacokinetic, pharmacodynamics, immunogenicity and preliminary clinical efficacy of QLS4131 in subjects with…
- Trial name
- NCT07001839
- Testing
- QLS4131 for Injection.
- Volunteers
- 108 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Systemic Lupus Erythematosus
Myeloid Derived Suppressor Cells in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is a chronic invalidating chronic condition, with potential articular, cutaneous, renal, and neurologic involvement.
- Trial name
- MDSC-SLE (NCT05424627)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Central Hospital, Nancy, France
Systemic Lupus Erythematosus
Exercise and Arterial Stiffness in Systemic Lupus Erythematosus
Patients with Systemic Lupus Erythematosus (SLE) have increased arterial stiffness, which leads to cardiovascular diseases (CVD) of arteriosclerotic origin, which are the main cause of mortality in these patients.
- Trial name
- EJERCITALES (NCT03107442)
- Testing
- Aerobic exercise
- Where
- Spain
- Volunteers
- 58 people
- Sponsor
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Diabetes, Cardiovascular Disease
A Complex Contraception Registry
The investigators will conduct a prospective observational cohort study to investigate factors that influence contraceptive method utilization among women with medical conditions.
- Conditions
- Diabetes, Cardiovascular Disease, Epilepsy, Migraine
- Trial name
- NCT02219269
- Where
- 5 sites in United States
- Volunteers
- 97 people
- Sponsor
- University of California, San Diego
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
This is a Phase 1 single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06835375 in subjects with seropositive SLE or RA.
- Trial name
- NCT03334851
- Testing
- PF-06835375
- Where
- 17 sites in United States
- Volunteers
- 74 people
- Sponsor
- Pfizer
Systemic Lupus Erythematosus
Safety of Estrogens in Lupus: Hormone Replacement Therapy
Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen.
- Trial name
- NCT00000419
- Testing
- Premarin and Provera
- Where
- 16 sites in United States
- Volunteers
- 350 people
- Sponsor
- NYU Langone Health
Nephritis, Lupus
Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis
Evaluation the clinical efficacy and safety profile of glucocorticosteroid combined with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F) in the treatment of patients with lupus nephritis.
- Trial name
- NCT01646736
- Testing
- Tripterygium wilfordii Hook F, Cyclophosphamide, GC
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking Union Medical College Hospital
Lupus Nephritis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with…
- Trial name
- POSTERITY (NCT05039619)
- Testing
- Obinutuzumab, Mycophenolate Mofetil, Acetaminophen/paracetamol
- Where
- 44 sites in United States, Brazil and 10 more
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
In this study, researchers will learn more about a study drug called BIIB059 (litifilimab) in participants with cutaneous lupus erythematosus (CLE).
- Trial name
- AMETHYST LTE (NCT06044337)
- Testing
- BIIB059 (litifilimab)
- Where
- 104 sites in United States, Argentina and 23 more
- Volunteers
- 306 people
- Sponsor
- Biogen
Lupus Erythematosus, Graft-versus-host Disease
Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
The main goal of the study is to determine if bone marrow transplant (BMT) from a less specific pool of donors in combination with high dose cyclophosphamide can induce remission of refractory systemic lupus erythematosus.
- Trial name
- NCT02080195
- Testing
- Cyclophosphamide, Fludarabine, Tacrolimus
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Systemic Lupus Erythematosus
Belimumab Assessment of Safety in SLE
The purpose of this study is to further enhance the existing knowledge regarding the side effects of belimumab when given with other lupus medicines to adults with active systemic lupus erythematosus (SLE).
- Trial name
- BASE (NCT01705977)
- Testing
- Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Where
- 250 sites in United States, Argentina and 31 more
- Volunteers
- 4,019 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers
The intent of this study is to evaluate the safety and tolerability of single escalating subcutaneous doses of CUG252 in healthy adult subjects.
- Trial name
- NCT05328557
- Testing
- CUG252
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Cugene Inc.
Systemic Lupus Erythematosus
Transcutaneous Vagus Nerve Stimulation for the Treatment of Lupus
This is a 3-month double blinded randomized controlled study of transcutaneous electrical vagus nerve stimulation (tVNS) compared to a sham stimulation for the treatment of patients with active systemic lupus erythematosus (SLE).
- Trial name
- TRUST (NCT02917265)
- Testing
- TENS for vagus stimulation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Aikaterini Thanou
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus and Accelerated Aging
The study aims at evaluating the phenomena of immune system aging in patients with Systemic lupus erythematosus.
- Trial name
- LUPAGE (NCT05698173)
- Testing
- blood sample
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune…
- Conditions
- Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Juvenile Systemic Lupus Erythematosus
- Trial name
- BTNDV-ARD (NCT07087912)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.